© MediPaper 2016 ASCO 2016 Atezolizumab Data MediPaper Study / AbstractPhIndicationLineNArms1 o EPORRmPFS (Mo) mOS (Mo) OS rate LBA4500Results coming after.

Slides:

Advertisements

Similar presentations

James R. Rigas Comprehensive Thoracic Oncology Program

Advertisements

Metastatic Gastric Cancer

Paz-Ares LG et al. Proc ASCO 2011;Abstract CRA7510.

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab:

Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.

Presented by Martin H. Cohen, M.D. at the 27 July 2004 meeting of the Oncologic Drugs Advisory Committee.

First-Line TKI Use in EGFR Mutation-Positive NSCLC

Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer Flaherty K et al. American Society of Clinical.

Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results.

O’Shaughnessy J et al. Proc ASCO 2011;Abstract 1007.

Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal.

Adam Heathfield, PhD Senior Director, Worldwide Policy, Pfizer Inc. September 25, 2013 Personalised Medicine – an industry perspective.

Gemcitabine + Cisplatin +/- Bevacizumab as 1st-line Treatment of Advanced NSCLC: AVAiL Study Manegold PASCO 25:#7514, 2007/Ann.

Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.

A Multicentre Phase II Study of Cisplatin (C), Gemcitabine (G), and Bevacizumab (B) as First-Line Chemotherapy for Metastatic.

Cabozantinib (XL184) in metastatic castration- resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation.

1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.

PHASE II RANDOMIZED STUDY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 – POSITIVE.

May 29 - June 2, 2015 Atezolizumab (MPDL3280A) Shows Favorable Tolerability, Promising Activity in Urothelial Bladder Cancer CCO Independent Conference.

ASCO 2016 Nivolumab Data Study Ph Indication Line N Arms 1o EP ORR

© MediPaper 2016 ASCO 2016 Palbociclib (Ibrance™) Data MediPaper Study / AbstractPhIndicationLineNN BiomarkerMethodologyArms1 o EPORRCBRDCRmPF S (Mo) PFS.

© MediPaper 2016 ASCO 2016 Ipilimumab Data - Melanoma MediPaper Study / AbstractPhIndicationLineNArms1 o EPORRmDR (Mo) mPFS (Mo) PFS ratemOS (Mo) OS rate.

Single-agent nab-Paclitaxel Given Weekly (3/4) as First-line Therapy for Metastatic Breast Cancer (An International Oncology Network Study, #I )

ASCO 2016 Pembrolizumab Data - Melanoma

POPLAR: Atezolizumab Improved Survival vs Docetaxel in Patients With Advanced NSCLC and Increasing Levels of PD-L1 Expression CCO Independent Conference.

May 29 – June 2, 2015 Lung Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* *CCO is an independent medical education company.

May 29 - June 2, 2015 KEYNOTE-028: Antitumor Activity With Pembrolizumab in Patients With PD-L1- Positive Extensive-Stage SCLC CCO Independent Conference.

CCO Independent Conference Coverage

ESMO 2016 Nivolumab Data Study Ph Indication Line N Arms 1o EP ORR mDR

Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in.

Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC

CCO Independent Conference Highlights

KEYNOTE-045: Updated Survival Analysis of Phase III Trial of Pembrolizumab vs Paclitaxel, Docetaxel, or Vinflunine in Pts With Advanced Urothelial Carcinoma.

ESMO 2016 Durvalumab Data Study / Abstract Ph Indication Line N Arms

Brian Boulmay, MD LSUHSC- New Orleans Section of Hematology & Oncology

KEYNOTE-028: Pembrolizumab in PD-L1+, ER+/HER2- Breast Cancer

CCO Independent Conference Highlights

CCO Independent Conference Coverage

CCO Independent Conference Highlights

Alessandra Gennari, MD PhD

N Engl J Med; Volume 373(17): ; October 22, 2015

KEYNOTE-086 (Cohort A): Phase II Evaluation of Pembrolizumab Monotherapy in Heavily Pretreated Metastatic TNBC CCO Independent Conference Highlights* of.

Azienda Ospedaliero Universitaria Policlinico Modena

CCO Independent Conference Coverage

IMvigor 210 (Cohort 1): First-line Atezolizumab in Cisplatin-Ineligible Metastatic Urothelial Carcinoma CCO Independent Conference Coverage* of the 2016.

ECHO-204: Preliminary Results of Phase I/II Trial of Epacadostat + Nivolumab in Advanced Solid Tumors CCO Independent Conference Highlights* of the 2017.

CCO Independent Conference Coverage

ASPEN: Prolonged PFS With Sunitinib vs Everolimus in Nonclear-Cell RCC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -

CCO Independent Conference Highlights

STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.

Phase I/II Study of Lorlatinib in Advanced ALK+ or ROS1+ NSCLC

NCI/CTEP 7435: Eribulin Active, Tolerable in Urothelial Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,

CCO Independent Conference Coverage

Combined Inhibition of PD-L1, MEK, and BRAF Active in Advanced Melanoma CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -

KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

CCO Independent Conference Coverage

Abraxane-Pembro nei carcinomi uroteliali avanzati

CCO Independent Conference Coverage

Intervista a Lucio Crinò

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

Lancet Oncol 2016;17(11): Updated Results from KEYNOTE-021 Cohort G: A Randomized, Phase 2 Study of Pemetrexed and Carboplatin (PC) with or without.

A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.

Axel Grothey Professor of Oncology Mayo Clinic Rochester

Rossi A et al. Proc ASCO 2011;Abstract 8008.

Presented By Johanna Bendell at 2016 ASCO Annual Meeting

Domenica 03 giugno Highlight a cura di Filippo de Marinis

Progression-Free Survival Times Overall Survival Times

Lunedì 04 giugno Highlight a cura di Filippo de Marinis

R Hermann6, P Sportelli7, L Gardner7 and J Bendell8

Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.

Presentation transcript:

© MediPaper 2016 ASCO 2016 Atezolizumab Data MediPaper Study / AbstractPhIndicationLineNArms1 o EPORRmPFS (Mo) mOS (Mo) OS rate LBA4500Results coming after Sunday June 5, 11:00 AM CTZ POPLARPOPLAR 9028IINSCLC2 nd / 3 rd TC3 / IC3 23 TC3 / IC3 50 TC2/3 / IC 2/3 55 TC2/3 / IC 2/3 93 TC1/2/3 / IC1/2/3 102 TC1/2/3 / IC1/2/3 51 TC0/ IC0 41 TC0/ IC0 49 Squamous 48 Squamous 95 Non-Squamous 95 Non-Squamous Atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w Atezo 1200 mg IV q3w Doc q3w atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w OS NR POPLARPOPLAR 9032IINSCLC2 nd / 3 rd 144 imRECIST 144 RECIST 57 Atezo after PD 30 Other after PD Atezo 1200 mg IV q3w Atezo 1200 mg IV q3w Atezo 1200 q3w —> PD —> Atezo dose ND Atezo 1200 q3w —> PD —> Other Tx OS17% 15% 14% IMvigor210IImUC ≧ 2 nd 100 IC2/3 imRECIST 207 IC1/2/3 imRECIST 310 IC0/1/2/3 imRECIST 100 IC2/3 RECIST 207 IC1/2/3 RECIST 310 IC0/1/2/3 RECIST Plat CTx —> PD —> R —> Atezo 1200 q3w 29% 23% 19% 26% 18% 15% (1- Yr) 40 (1- Yr) 37 (1- Yr) Abstract 35021bCRC ≧ 1 st 23 (22 KRASmu)Cobi + Atezo 800 q2wMTD (NR)17% Abstract 10091bmTNBC1 st 2 nd ≧ 3 rd ≧ 1 st (All) Atezo 800 q2w + Pac Safety & tolerability (NR) 67%, 89% 35%, 75% 29%, 43% 42%, 71% (Conf., TBC) Treatments: Atezo 800 = Atezolizumab 800 mg IV; Atezo 1200 = Atezolizumab 1200 mg IV; Cobi = cobimetinib mg daily 3wk on, 1 wk off; Doc = docetaxel 75 mg/m 2 ; IV; Pac = Nab-paclitaxel 125 mg/m 2 on d1,8,15 of 28 day cycles;Tx = Treatment. Abbreviations: 1 o EP = Primary Endpoint; BRAFmu = BRAF mutation; C2 = Cohort 2; Conf. = Confirmed; CRC = Colorectal Cancer; IC3/2/1/0 = high/medium/low/very low PDL1 expression on tumor-infiltrating immune cells; mOS = median Overall Survival; Mo = Months; mPFS = median Progression Free Survival; mTNBC = metastatic Triple Negative Breast Cancer; mUC = metastatic urothelial cancer; NR = Not Reported; NSCLC = non-small cell lung cancer; ORR = Overall Response Rate; OS; Overall Survival; PFS: Progression Free Survival; Ph = Phase; qXwk = every X weeks; R = Registration; TBC = To be confirmed; TC3/2/1/0 = high/medium/low/very low PD-L1 expression on tumor cells; Wk = Weeks; Yr = Year.

© MediPaper 2016 ASCO 2016 Atezolizumab Data Courtesy of MediPaper Medical Writers - Medi-Paper.comMedi-Paper.com Study / AbstractPhIndicationLineNArms1 o EPORRmPFS (Mo) mOS (Mo) OS rate LBA4500Results coming after Sunday June 5, 11:00 AM CTZ POPLARPOPLAR 9028IINSCLC2 nd / 3 rd TC3 / IC3 23 TC3 / IC3 50 TC2/3 / IC 2/3 55 TC2/3 / IC 2/3 93 TC1/2/3 / IC1/2/3 102 TC1/2/3 / IC1/2/3 51 TC0/ IC0 41 TC0/ IC0 49 Squamous 48 Squamous 95 Non-Squamous 95 Non-Squamous Atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w Atezo 1200 mg IV q3w Doc q3w atezo 1200 q3w Doc q3w Atezo 1200 q3w Doc q3w OS NR POPLARPOPLAR 9032IINSCLC2 nd / 3 rd 144 imRECIST 144 RECIST 57 Atezo after PD 30 Other after PD Atezo 1200 mg IV q3w Atezo 1200 mg IV q3w Atezo 1200 q3w —> PD —> Atezo dose ND Atezo 1200 q3w —> PD —> Other Tx OS17% 15% 14% IMvigor210IImUC ≧ 2 nd 100 IC2/3 imRECIST 207 IC1/2/3 imRECIST 310 IC0/1/2/3 imRECIST 100 IC2/3 RECIST 207 IC1/2/3 RECIST 310 IC0/1/2/3 RECIST Plat CTx —> PD —> R —> Atezo 1200 q3w 29% 23% 19% 26% 18% 15% (1- Yr) 40 (1- Yr) 37 (1- Yr) Abstract 35021bCRC ≧ 1 st 23 (22 KRASmu)Cobi + Atezo 800 q2wMTD (NR)17% Abstract 10091bmTNBC1 st 2 nd ≧ 3 rd ≧ 1 st (All) Atezo 800 q2w + Pac Safety & tolerability (NR) 67%, 89% 35%, 75% 29%, 43% 42%, 71% (Conf., TBC) Treatments: Atezo 800 = Atezolizumab 800 mg IV; Atezo 1200 = Atezolizumab 1200 mg IV; Cobi = cobimetinib mg daily 3wk on, 1 wk off; Doc = docetaxel 75 mg/m 2 ; IV; Pac = Nab-paclitaxel 125 mg/m 2 on d1,8,15 of 28 day cycles;Tx = Treatment. Abbreviations: 1 o EP = Primary Endpoint; BRAFmu = BRAF mutation; C2 = Cohort 2; Conf. = Confirmed; CRC = Colorectal Cancer; IC3/2/1/0 = high/medium/low/very low PDL1 expression on tumor-infiltrating immune cells; mOS = median Overall Survival; Mo = Months; mPFS = median Progression Free Survival; mTNBC = metastatic Triple Negative Breast Cancer; mUC = metastatic urothelial cancer; NR = Not Reported; NSCLC = non-small cell lung cancer; ORR = Overall Response Rate; OS; Overall Survival; PFS: Progression Free Survival; Ph = Phase; qXwk = every X weeks; R = Registration; TBC = To be confirmed; TC3/2/1/0 = high/medium/low/very low PD-L1 expression on tumor cells; Wk = Weeks; Yr = Year.